China's Weight-Loss Drug Market Faces Surge in Demand and Rising Competition

With obesity rates climbing, both foreign and domestic pharmaceutical companies vie for market dominance amid regulatory challenges.

Novo Nordisk's Ozempic and Wegovy see soaring sales in China, driven by their weight-loss effects.
Chinese firms are developing numerous generic versions of these drugs, anticipating the expiration of Novo's patent in 2026.
Counterfeit weight-loss drugs are proliferating online, prompting increased regulatory scrutiny.
High prices on e-commerce platforms reflect the intense demand for effective weight-loss solutions.
Future market leadership hinges on regulatory outcomes and the ability to scale production.